Aurobindo Pharma Ltd vs Indoco Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1428 as of 05 May 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Indoco Remedies Ltd changed from 28.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Indoco Remedies Ltd changed from ₹ 2658 crore on March 2021 to ₹ 2152 crore on March 2025 . This represents a CAGR of -4.14% over 5 years The revenue of Aurobindo Pharma Ltd for the Dec '25 is ₹ 8833 crore as compare to the Sep '25 revenue of ₹ 8407 crore. This represent the growth of 5.07% The revenue of Indoco Remedies Ltd for the Dec '25 is ₹ 446.34 crore as compare to the Sep '25 revenue of ₹ 485.43 crore. This represent the decline of -8.05% The ebitda of Aurobindo Pharma Ltd for the Dec '25 is ₹ 1896 crore as compare to the Sep '25 ebitda of ₹ 1800 crore. This represent the growth of 5.31% The ebitda of Indoco Remedies Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 43.28 crore. This represent the decline of -39.14% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 909.8 crore over 7 quarters. This represents a CAGR of -0.53% The net profit of Indoco Remedies Ltd changed from ₹ 1.82 crore to ₹ -29.45 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Indoco Remedies Ltd changed from 14.96 % on March 2021 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Indoco Remedies Ltd

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

FAQs for the comparison of Aurobindo Pharma Ltd and Indoco Remedies Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Indoco Remedies Ltd?

Market cap of Aurobindo Pharma Ltd is 79,906 Cr while Market cap of Indoco Remedies Ltd is 1,945 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Indoco Remedies Ltd?

The stock performance of Aurobindo Pharma Ltd and Indoco Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Indoco Remedies Ltd?

As of May 5, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1375.8. On the other hand, Indoco Remedies Ltd stock price is INR ₹210.8.

How do dividend payouts of Aurobindo Pharma Ltd and Indoco Remedies Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Indoco Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.